Evidence map›Paper›PMID 37442201›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2023

Rational nanoparticle design: Optimization using insights from experiments and mathematical models.

Owen Richfield, Alexandra S Piotrowski-Daspit, Kwangsoo Shin, W Mark Saltzman

Abstract readReview
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Owen RichfieldDepartment of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.
Alexandra S Piotrowski-DaspitDepartment of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.
Kwangsoo ShinDepartment of Biomedical Engineering, Yale University, New Haven, CT 06511, USA.
W Mark SaltzmanDepartment of Biomedical Engineering, Yale University, New Haven, CT 06511, USA; Department of Cellular & Molecular Physiology, Yale University, New Haven, CT 06511, USA; Department of Chemical & Environmental Engineering, Yale University, New Haven, CT 06511, USA; Department of Dermatology, Yale University, New Haven, CT 06511, USA. Electronic address: mark.saltzman@yale.edu.

Funding

PATHOPHYSIOLOGY OF ACUTE AND CHRONIC RENAL DISEASET32DK007276 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S., CANTLEY, LLOYD G · 1986 to 2022
$9.3M
CED of Nanoparticles Loading with Novel Agents for Improved Treatment of GliomasR01CA149128 · NCI · YALE UNIVERSITY · PI SALTZMAN, W. MARK · 2011 to 2020
$3.5M
Poly(amine-co-ester)s for Targeted Delivery In Vivo of Gene Editing Agents to Bone Marrow and LungUG3HL147352 · NHLBI · YALE UNIVERSITY · PI GLAZER, PETER M, SALTZMAN, W. MARK · 2018 to 2020
$2.4M
Poly(amine-co-ester)s for targeted delivery of gene editing agents to treat cystic fibrosis in animal models: SCGE Disease Models Studies SupplementUH3HL147352 · NHLBI · YALE UNIVERSITY · PI GLAZER, PETER M, SALTZMAN, W. MARK · 2021 to 2022
$2.4M
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft EndotheliumU01AI132895 · NIAID · YALE UNIVERSITY · PI POBER, JORDAN S, SALTZMAN, W. MARK · 2017 to 2021
$2.2M
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic Fibrosis- SupplementR00HL151806 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIOTROWSKI-DASPIT, ALEXANDRA SARAH ANNUKKA · 2023 to 2025
$856k
Developing Gene Editing Therapeutics, Biodegradable Polymeric Delivery Vehicles, and High-throughput Platforms for the Treatment of Cystic FibrosisK99HL151806 · NHLBI · YALE UNIVERSITY · PI PIOTROWSKI-DASPIT, ALEXANDRA SARAH ANNUKKA · 2021 to 2022
$255k
NCI NIH HHS R01 CA149128NHLBI NIH HHS K99 HL151806NHLBI NIH HHS R00 HL151806NHLBI NIH HHS UG3 HL147352NHLBI NIH HHS UH3 HL147352NIAID NIH HHS U01 AI132895NIDDK NIH HHS T32 DK007276
6 · The paper itself

Abstract

Polymeric nanoparticles are highly tunable drug delivery systems that show promise in targeting therapeutics to specific sites within the body. Rational nanoparticle design can make use of mathematical models to organize and extend experimental data, allowing for optimization of nanoparticles for particular drug delivery applications. While rational nanoparticle design is attractive from the standpoint of improving therapy and reducing unnecessary experiments, it has yet to be fully realized. The difficulty lies in the complexity of nanoparticle structure and behavior, which is added to the complexity of the physiological mechanisms involved in nanoparticle distribution throughout the body. In this review, we discuss the most important aspects of rational design of polymeric nanoparticles. Ultimately, we conclude that many experimental datasets are required to fully model polymeric nanoparticle behavior at multiple scales. Further, we suggest ways to consider the limitations and uncertainty of experimental data in creating nanoparticle design optimization schema, which we call quantitative nanoparticle design frameworks.

Indexed as

Models, TheoreticalNanoparticlesDrug Delivery SystemsPolymersPolymersMultiscale mathematical modelingNanoparticle pharmacokineticsPhysiologically based pharmacokineticsPolymeric nanoparticlesRational nanoparticle design

Identifiers

PMID37442201
PMCPMC10529591

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.